Enzymotec Announces $3.5m R&D Investments for 2007
This announcement, follows earlier announcement made by the company regarding a third plant expansion for 2006, the signing of several research contracts with leading health centers and announced of the publication of its CardiaBeat-McGill study.
11/12/06 Enzymotec has announced its R&D expenditure plan for 2007, which will reach $3.5M. This investment shall cover all the areas of development, including: cognitive, CVD and Infant nutrition.
This announcement, follows earlier announcement made by the company regarding a third plant expansion for 2006, the signing of several research contracts with leading health centers and announced of the publication of its CardiaBeat-McGill study at the December issue of the AJCN.
"We strongly believe that our R&D strategy and expenditure were a major contributor to our success and ability to become a major global player in health areas where we operate. Indeed, our customers and partners are aware and undoubtedly appreciate our long-term commitment to re-invest a major portion of our revenues back into R&D and thus increase the value of their solutions through novel ingredients and science", says Dr. Ariel Katz, Enzymotec CEO.
Enzymotec an Israeli company, is a developer and manufacturer of innovative biofunctional ingredients for dietary supplements, functional foods and infant formula.
The company develops and produces novel, lipid based ingredients among which are: CardiaBeat, SharpPS and SharpPS GOLD for improving cognitive performance and InFat for balanced nutrition for babies and toddlers.
